
Eledon Pharmaceuticals, Inc.
ELDNNasdaqCIK 1404281HealthcareFiscal year ends Dec 31
Reports and events: 214 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-11-0916:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062007 |
| 2023-11-0216:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-058279 |
| 2023-10-0207:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-050925 |
| 2023-09-2119:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-23-049046 |
| 2023-09-1316:42 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-047951 |
| 2023-08-1017:01 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-041456 |
| 2023-08-1007:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-040949 |
| 2023-06-2219:51 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-23-029259 |
| 2023-05-1117:06 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-021372 |
| 2023-05-1116:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-021198 |
| 2023-05-0116:51 ET | DEF 14A | Proxy statement | 0000950170-23-016306 |
| 2023-05-0107:27 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-016017 |
| 2023-03-3017:01 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-011011 |
| 2023-03-3016:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-010924 |
| 2023-01-0908:47 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-000465 |
| 2022-11-1417:10 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-025007 |
| 2022-11-1416:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-024980 |
| 2022-08-1117:01 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-016935 |
| 2022-08-1116:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-016850 |
| 2022-06-2318:13 ET | 8-K | 5.07 Shareholder vote results | 0000950170-22-011978 |
| 2022-05-3106:38 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-22-010890 |
| 2022-05-1217:01 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001564590-22-019921 |
| 2022-05-1216:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-019851 |
| 2022-04-2817:04 ET | DEF 14A | Proxy statementPeriod 2022-06-21 | 0001564590-22-016509 |
| 2022-03-2417:02 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001564590-22-011698 |
| 2022-03-2416:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-011680 |
| 2022-01-1316:00 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001564590-22-001203 |
| 2021-11-1206:36 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001564590-21-056417 |
| 2021-11-1206:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-056413 |
| 2021-08-1217:01 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-044038 |
| 2021-08-1216:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-043944 |
| 2021-08-0209:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-039644 |
| 2021-07-0208:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-035584 |
| 2021-06-1616:00 ET | 8-K | 5.07 Shareholder vote results | 0001564590-21-033187 |
| 2021-05-1418:11 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-027695 |
| 2021-05-1316:22 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-027581 |
| 2021-04-2916:34 ET | DEF 14A | Proxy statementPeriod 2021-06-15 | 0001564590-21-022013 |
| 2021-04-2719:40 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001564590-21-020624 |
| 2021-03-3121:01 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-016828 |
| 2021-03-1514:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-013094 |
| 2021-01-0708:00 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-21-003750 |
| 2021-01-0516:38 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-21-000013 |
| 2021-01-0516:10 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-21-000921 |
| 2020-12-2208:16 ET | 8-K | 5.07 Shareholder vote results | 0001193125-20-323914 |
| 2020-12-1017:00 ET | 8-K | 5.03 Amendment to articles or bylaws | 0001564590-20-056746 |
| 2020-12-0417:12 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-20-000932 |
| 2020-11-2016:39 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-20-000897 |
| 2020-11-2016:18 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001564590-20-054793 |
| 2020-11-2008:32 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001193125-20-298749 |
| 2020-11-2008:30 ET | DEF 14A | Proxy statementPeriod 2020-12-18 | 0001193125-20-298745 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.